<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04490629</url>
  </required_header>
  <id_info>
    <org_study_id>2017-126</org_study_id>
    <nct_id>NCT04490629</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of a Latest Dural Substitute</brief_title>
  <acronym>ESLO</acronym>
  <official_title>A Prospective, Multi-center, Randomized, Parallel-controlled Clinical Trial Evaluating the Efficacy and Safety of Lyoplant Onlay in Repairing Cerebral Dura Mater</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, multi-center, randomized, parallel-controlled clinical trial was designed&#xD;
      to evaluate the efficacy and safety of Lyoplant Onlay in repairing cerebral dura mater.&#xD;
      DURAFORM was regarded as the control group. a total of 80 patients were randomized into&#xD;
      experimental and control group (1:1).Data were collected on complications resulting in CSF&#xD;
      leaks, surgical site infections, instrument performance parameterized other neurological&#xD;
      complications within 30 days. Surgeons also provided data on the ease of use of the dural&#xD;
      sealing techniques, as well as preparation and application times. The above-mentioned date&#xD;
      were used to evaluate the efficacy and safety of Lyoplant Onlay .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>surgical successful rate</measure>
    <time_frame>at 30 days post surgery</time_frame>
    <description>proportion of treated patients free of CSF leak diagnosed by physical examination, biochemical assay, or imaging study within 30 d of the surgical procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>neurosurgical complication</measure>
    <time_frame>2 days post surgery/10 days post surgery/at 30 days post surgery</time_frame>
    <description>Incidence of intracranial infection at 2 days after operation，at discharge，and at 30 days after operation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cerebrospinal Fluid Leak</condition>
  <arm_group>
    <arm_group_label>DURAFORM</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>DURAFORM was used in repairing cerebral dura mater.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lyoplant Onlay</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lyoplant Onlay was used in repairing cerebral dura mater.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lyoplant Onlay</intervention_name>
    <description>Lyoplant Onlay is a kind of latest artificial Dura Mater</description>
    <arm_group_label>Lyoplant Onlay</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DURAFORM</intervention_name>
    <description>DURAFORM is a kind of conventional artificial Dura Mater</description>
    <arm_group_label>DURAFORM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient between the ages of 18 and 75 years scheduled for elective cranial surgery&#xD;
             involving a dural incision.&#xD;
&#xD;
          -  Dural defects and surgical incision was classifed as level 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  local or systemic infection.&#xD;
&#xD;
          -  patients with known allergy to Equipment components&#xD;
&#xD;
          -  a history of traumatic head injury&#xD;
&#xD;
          -  a compromised immune system or autoimmune disease&#xD;
&#xD;
          -  patients who should not participate based on the surgeon's opinion&#xD;
&#xD;
          -  patients participating in any other drug or device trial.&#xD;
&#xD;
          -  expected survival time &lt;12 months&#xD;
&#xD;
          -  underwent chemoradiotherapy 3 months before randomization&#xD;
&#xD;
          -  uncontrolled diabetes and malignant tumor&#xD;
&#xD;
          -  women who were pregnant, lactating, or wished to become pregnant during the study;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jianmin zhang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of neurosurgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianmin Zhang, M.D.</last_name>
    <phone>+86 0571 87784755</phone>
    <email>zjm135@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jianmin Zhang</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianmin Zhang, M.D., Ph.D.</last_name>
      <phone>+86 0571 87784755.</phone>
      <email>zjm135@zju.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Jianmin Zhang, M.D.，Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Junming Zhu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 16, 2020</study_first_submitted>
  <study_first_submitted_qc>July 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2020</study_first_posted>
  <last_update_submitted>July 26, 2020</last_update_submitted>
  <last_update_submitted_qc>July 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dura Mater</keyword>
  <keyword>Cerebrospinal Fluid Leak</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrospinal Fluid Leak</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The committee will debate whether to share IPD depending on the circumstances. Because some patients are unwilling to make their condition known.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

